Imanishi Takashi, Uemura Riko
Education and Research Center for Clinical Pharmacy, Kyoto Pharmaceutical University.
Yakugaku Zasshi. 2025;145(2):155-161. doi: 10.1248/yakushi.24-00158.
This study examines current OTC pharmaceuticals in Japan categorized as potential substances for abuse and discusses future initiatives for drug abuse prevention.
The Pharmaceuticals and Medical Devices Agency package inserts search function was used to identify OTC pharmaceuticals containing substances prone to abuse. Subsequently, the corresponding OTC pharmaceuticals containing the designated ingredients were investigated, analyzing their therapeutic and risk categories.
In total, 1427 (13.9%) OTC pharmaceuticals contained the designated ingredients, with those containing methylephedrine and dihydrocodeine accounting for the majority (1245/1427, 87.2%). Among the therapeutic categories, oral cold medicines were predominant at 564, followed by antitussives and expectorants at 213, and oral rhinitis medicines at 100. Regarding risk categories, designated schedule II pharmaceuticals predominated in 9 out of 11 therapeutic category classifications.
Designated schedule II pharmaceuticals, such as oral cold medicines, antitussives and expectorants, and oral rhinitis medicines, pose a high risk of drug abuse. Addressing this challenge necessitates collaboration between pharmacists and registered sales clerks to implement preventive measures aligned with current trends in drug abuse.
本研究对日本目前归类为潜在滥用物质的非处方药品进行了调查,并探讨了未来预防药物滥用的举措。
利用药品和医疗器械局包装说明书搜索功能,识别含有易被滥用物质的非处方药品。随后,对含有指定成分的相应非处方药品进行调查,分析其治疗类别和风险类别。
共有1427种(13.9%)非处方药品含有指定成分,其中含有甲基麻黄碱和二氢可待因的药品占大多数(1245/1427,87.2%)。在治疗类别中,口服感冒药占主导地位,有564种,其次是止咳祛痰药,有213种,口服鼻炎药有100种。在风险类别方面,在11种治疗类别分类中的9种中,指定的附表II药品占主导地位。
指定的附表II药品,如口服感冒药、止咳祛痰药和口服鼻炎药,存在很高的药物滥用风险。应对这一挑战需要药剂师和注册店员合作,实施与当前药物滥用趋势相一致的预防措施。